ADVERTISEMENT
remdesivir image x

Gilead’s remdesivir offers little benefit for coronavirus patients in early trial

The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists